Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
King Charles shares cancer treatment update, says it's a 'personal blessing' - 2Improving as a Pioneer: Examples from My Vocation
- 3Florida has quietly become America's execution capital
- 4Reality TV star Spencer Pratt, who lost his home in Palisades Fire, is running for mayor of Los Angeles
- 5Phonetic Associations: A Survey of \Interfacing Worldwide People group\ Language Trade Application
- Ghassan Al-Duhaini to replace Abu Shabab as Popular Forces leader in Gaza
- The Red Sea strategy: What does Israel stand to gain from recognizing Somaliland?
- What we know about the 'Stranger Things' spinoff — plus the one cast member who guessed it correctly
- See the moon shine with Saturn in the southern sky after sunset Dec. 26
- Sahel coups push Africa to top of global democratic declines, report finds
- Huge rotating structure of galaxies and dark matter is detected
- Brazil's former President Jair Bolsonaro seeks house arrest for prison time citing health issues
- Figure out How to Stay away from Normal Handshaking Missteps
- Current Chateaus: Advancement and Style
